NOTCH3 drives fatty acid oxidation and ferroptosis resistance in aggressive meningiomas - Summary - MDSpire

NOTCH3 drives fatty acid oxidation and ferroptosis resistance in aggressive meningiomas

  • By

  • Nishanth S. Sadagopan

  • Mateo Gomez

  • Shashwat Tripathi

  • Leah K. Billingham

  • Susan L. DeLay

  • Martha A. Cady

  • Harrshavasan T. S. Congivaram

  • Tzu-Yi Chia

  • Hanxiao Wan

  • Si Wang

  • David R. Raleigh

  • Faith C. Kaluba

  • Evan C. Lien

  • Amy B. Heimberger

  • Catalina Lee-Chang

  • Mark W. Youngblood

  • Stephen T. Magill

  • Jason M. Miska

  • September 9, 2025

  • 0 min

Share

Objective:

To investigate the role of NOTCH3 in lipid metabolism and its implications for tumor growth and resistance in meningiomas, particularly focusing on its metabolic effects.

Key Findings:
  • NOTCH3 activation leads to depletion of fatty acids used for fatty acid oxidation (FAO), indicating a shift in metabolic reliance.
  • This metabolic alteration provides resistance to ferroptosis in meningioma cells, suggesting a survival advantage.
  • Meningiomas expressing NOTCH3 exhibit a poor prognosis due to enhanced malignancy, highlighting the need for targeted therapies.
Interpretation:

The findings suggest that NOTCH3 not only promotes tumor growth but also alters metabolic pathways that confer resistance to cell death, highlighting its potential as a therapeutic target in meningiomas, warranting further investigation into specific inhibitors.

Limitations:
  • The study primarily focuses on in vitro models, which may not fully replicate in vivo tumor behavior, such as the tumor microenvironment and systemic interactions.
  • Further research is needed to explore the clinical implications of NOTCH3 targeting in meningioma treatment, including potential side effects and efficacy in human patients.
Conclusion:

NOTCH3 plays a critical role in the metabolic adaptation of meningiomas, making it a promising target for therapeutic intervention.

Original Source(s)

NOTCH3 drives fatty acid oxidation and ferroptosis resistance in aggressive meningiomas

  • by Nishanth S. Sadagopan, Mateo Gomez, Shashwat Tripathi, Leah K. Billingham, Susan L. DeLay, Martha A. Cady, Harrshavasan T. S. Congivaram, Tzu-Yi Chia, Hanxiao Wan, Si Wang, David R. Raleigh, Faith C. Kaluba, Evan C. Lien, Amy B. Heimberger, Catalina Lee-Chang, Mark W. Youngblood, Stephen T. Magill, Jason M. Miska

  • September 9, 2025

Related Content

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

High-grade astrocytoma with piloid features: a case report of comprehensive management